Englander-linked funds report 4.6% Quoin Pharmaceuticals (QNRX) stake

Rhea-AI Filing Summary

A group of investment entities associated with Israel A. Englander, including Integrated Core Strategies (US) LLC and Millennium Management LLC, reports beneficial ownership of 2,618,595 Quoin Pharmaceuticals ordinary shares, representing 4.6% of the class as of December 31, 2025.

The group reports only shared voting and dispositive power over these shares and no sole power. They state they have ceased to be beneficial owners of more than 5% of the outstanding ordinary shares and certify that the holdings are not for the purpose of influencing control of Quoin Pharmaceuticals.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Quoin Pharmaceuticals Ltd.

(Name of Issuer)

Ordinary Shares, no par value per share

(Title of Class of Securities)

74907L409

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74907L409

1

Names of Reporting Persons

Integrated Core Strategies (US) LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,618,595.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,618,595.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,618,595.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 74907L409

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,618,595.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,618,595.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,618,595.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 74907L409

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,618,595.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,618,595.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,618,595.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 74907L409

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,618,595.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,618,595.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,618,595.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Quoin Pharmaceuticals Ltd.
(b)	Address of issuer's principal executive offices: 42127 Pleasant Forest Court, Ashburn, Virginia 20148-7349
Item 2.
(a)	Name of person filing: Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Ordinary Shares, no par value per share
(e)	CUSIP No.: 74907L409
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page. As of the date of this filing, the reporting persons ceased to be beneficial owners of more than 5% of the outstanding Ordinary Shares.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Integrated Core Strategies (US) LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	02/10/2026

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	02/10/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	02/10/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	02/10/2026

Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner CUSIP number 74907L409 has been assigned to the Issuer's American Depositary Shares. Each American Depositary Share represents thirty-five Ordinary Shares. No CUSIP number has been assigned to the Issuer's Ordinary Shares.

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of February 10, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

FAQ

What stake in Quoin Pharmaceuticals (QNRX) does the Englander group report?

The Englander-associated entities report owning 2,618,595 ordinary shares, or 4.6% of Quoin Pharmaceuticals’ outstanding class as of December 31, 2025. This stake is held with shared voting and dispositive power, and they report no sole authority over these shares.

Which entities are reporting beneficial ownership in Quoin Pharmaceuticals (QNRX)?

The reporting persons are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. These related entities collectively report beneficial ownership of the same 2,618,595 ordinary shares of Quoin Pharmaceuticals’ ordinary shares.

Has the Englander group remained above the 5% ownership threshold in QNRX?

No. The reporting persons state they have ceased to be beneficial owners of more than 5% of Quoin’s outstanding ordinary shares. As of December 31, 2025, they report owning 4.6% of the class, below the 5% reporting threshold.

Does the Englander group seek to influence control of Quoin Pharmaceuticals (QNRX)?

The reporting persons certify that their Quoin holdings were not acquired and are not held to change or influence control of the issuer. They also state the securities are not held in connection with any transaction intended to affect control, other than limited nomination-related activities cited in the certification.

How are the Quoin Pharmaceuticals (QNRX) shares held by the Englander group controlled?

The filing notes the securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers. It also states this structure should not, by itself, be construed as an admission of beneficial ownership by Millennium entities or Israel A. Englander.

What security class and identifier does the Englander group disclosure for Quoin (QNRX) cover?

The disclosure covers Quoin Pharmaceuticals’ ordinary shares, no par value, linked to CUSIP 74907L409 assigned to its American Depositary Shares. Each American Depositary Share represents thirty-five ordinary shares, according to the comments accompanying the signatures.